• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Anat O. Stemmer-Rachamimov, MD


  • Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD.Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.Neuro Oncology. 2014 Aug(8):1057-66.
  • Pier DB, Nunes FP, Plotkin SR, Stemmer-Rachamimov AO, Kim JC, Shih HA, Brastianos P, Lin AE.Turner syndrome and meningioma: Support for a possible increased risk of neoplasia in Turner syndrome.Eur J Med Genet. 2014 Mar 25.
  • Prabhakar S, Goto J, Zhang X, Sena-Esteves M, Bronson R, Brockmann J, Gianni D, Wojtkiewicz GR, Chen JW, Stemmer-Rachamimov A, Kwiatkowski DJ, Breakefield XO.Correction: Stochastic Model of Tsc1 Lesions in Mouse Brain.PLoS ONE. 2013;8(11).
  • Mayes DA, Rizvi TA, Titus-Mitchell H, Oberst R, Ciraolo GM, Vorhees CV, Robinson AP, Miller SD, Cancelas JA, Stemmer-Rachamimov AO, Ratner N.Nf1 loss and Ras hyperactivation in oligodendrocytes induce NOS-driven defects in myelin and vasculature.Cell Rep. 2013 Sep 26;4(6):1197-212.
  • Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK.Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.Neuro Oncology. 2013 Aug;15(8):1079-87.
  • Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL.Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.Neoplasia. 2013 Jun;15(6):591-9.
  • Las Heras F, Martuza R, Caruso P, Rincon S, Stemmer-Rachamimov A.24-year-old woman with an internal auditory canal mass.Brain Pathol. 2013 May;23(3):361-2.
  • Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, Barker FG, Stemmer-Rachamimov A, Plotkin SR.Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients.PLoS ONE. 2013;8(3):e59941.
  • Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R.Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.Nat Genet. 2013 Mar;45(3):285-9.
  • Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M.Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.Am J Med Genet A. 2013 Mar;161(3):405-16.
  • Prabhakar S, Taherian M, Gianni D, Conlon TJ, Fulci G, Brockmann J, Stemmer-Rachamimov A, Sena-Esteves M, Breakefield XO, Brenner GJ.Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1.Hum Gene Ther. 2013 Feb;24(2):152-62.
  • Smith MJ, Walker JA, Shen Y, Stemmer-Rachamimov A, Gusella JF, Plotkin SR.Expression of SMARCB1 (INI1) mutations in familial schwannomatosis.Hum Mol Genet. 2012 Dec 15;21(24):5239-45.
  • Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR.Clinical features of schwannomatosis: a retrospective analysis of 87 patients.Oncologist. 2012;17(10):1317-22.
  • Fleming AJ, Hukin J, Rassekh R, Fryer C, Kim J, Stemmer-Rachamimov A, Birks DK, Huang A, Yip S, Dunham C.Atypical teratoid rhabdoid tumors (ATRTs): the British Columbia's Children's Hospital's experience, 1986-2006.Brain Pathol. 2012 Sep;22(5):625-35.
  • Huynh N, Stemmer-Rachamimov AO, Swearingen B, Cestari DM.Decreased vision and junctional scotoma from pituicytoma.Case Rep Ophthalmol. 2012 May;3(2):190-6.
  • Jeyaretna DS, Curry WT, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR.Exacerbation of cerebral radiation necrosis by bevacizumab.J Clin Oncol. 2011 Mar 1;29(7):e159-62.
  • Saydam O, Senol O, W├╝rdinger T, Mizrak A, Ozdener GB, Stemmer-Rachamimov AO, Yi M, Stephens RM, Krichevsky AM, Saydam N, Brenner GJ, Breakefield XO.miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways.Cancer Res. 2011 Feb 1;71(3):852-61.
  • Saydam O, Ozdener GB, Senol O, Mizrak A, Prabhakar S, Stemmer-Rachamimov AO, Breakefield XO, Brenner GJ.A novel imaging-compatible sciatic nerve schwannoma model.J Neurosci Methods. 2011 Jan 30;195(1):75-7.
  • Rodriguez FJ, Scheithauer BW, George D, Midha R, Maccollin M, Stemmer-Rachamimov AO.Superficial neurofibromas in the setting of schwannomatosis: nosologic implications.Acta Neuropathol. 2010 Dec 30.
  • Saydam O, Senol O, Schaaij-Visser TB, Pham TV, Piersma SR, Stemmer-Rachamimov AO, Wurdinger T, Peerdeman SM, Jimenez CR.Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas.J Proteome Res. 2010 Jan;9(1):485-94.
  • Saydam O, Shen Y, W├╝rdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO.Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.Mol Cell Biol. 2009 Nov;29(21):5923-40.
  • Stankovic KM, Mrugala MM, Martuza RL, Silver M, Betensky RA, Nadol JB, Stemmer-Rachamimov AO.Genetic determinants of hearing loss associated with vestibular schwannomas.Otol. Neurotol. 2009 Aug;30(5):661-7.
  • Shen Y, Nunes F, Stemmer-Rachamimov A, James M, Mohapatra G, Plotkin S, Betensky RA, Engler DA, Roy J, Ramesh V, Gusella JF.Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas.BMC Med Genomics. 2009;2:42.
  • Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E.Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.N Engl J Med. 2009 Jul 23;361(4):358-67.
  • James MF,Han S,Polizzano C,Plotkin SR,Manning BD,Stemmer-Rachamimov AO,Gusella JF,Ramesh V.NF2/Merlin is a Novel Negative Regulator of mTOR Complex 1 and Activation of mTORC1 is Associated with Meningioma and Schwannoma Growth.Mol Cell Biol. 2009 Aug;29(15):4250-61.
  • McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, Scheffzek K, Stemmer-Rachamimov AO, Sawyers CL, Brennan C, Messiaen L, Mellinghoff IK, Cichowski K.Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.Cancer Cell. 2009 Jul 7;16(1):44-54.
  • Wakimoto H,Kesari S,Farrell CJ,Curry WT Jr,Zaupa C,Aghi M,Kuroda T,Stemmer-Rachamimov A,Shah K,Liu TC,Jeyaretna DS,Debasitis J,Pruszak J,Martuza RL,Rabkin SD.Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.Cancer Res. 2009 Apr 15;69(8):3472-81.
  • Scheithauer BW,Swearingen B,Whyte ET,Auluck PK,Stemmer-Rachamimov AO.Ependymoma of the sella turcica: a variant of pituicytoma.Hum Pathol. 2009 Mar;40(3):435-40.
  • Chang Z,Guo CL,Ahronowitz I,Stemmer-Rachamimov AO,MacCollin M,Nunes FP.A role for the p53 pathway in the pathology of meningiomas with NF2 loss.J Neurooncol. 2009 Feb;91(3):265-70.
  • Jones GN,Tep C,Towns WH 2nd,Mihai G,Tonks ID,Kay GF,Schmalbrock PM,Stemmer-Rachamimov AO,Yoon SO,Kirschner LS.Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production.Neoplasia. 2008 Nov;10(11):1213-21.
  • Patil S, Perry A, Maccollin M, Dong S, Betensky RA, Yeh TH, Gutmann DH, Stemmer-Rachamimov AO.Immunohistochemical Analysis Supports a Role for INI1/SMARCB1 in Hereditary Forms of Schwannomas, but Not in Solitary, Sporadic Schwannomas.Brain Pathol. 2008 Oct;18(4):517-9.
  • Snuderl M,Chi SN,De Santis SM,Stemmer-Rachamimov AO,Betensky RA,De Girolami U,Kieran MW.Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas.J Neuropathol Exp Neurol. 2008 Sep;67(9):911-20.
  • Maguire CA,Meijer DH,LeRoy SG,Tierney LA,Broekman ML,Costa FF,Breakefield XO,Stemmer-Rachamimov A,Sena-Esteves M.Preventing growth of brain tumors by creating a zone of resistance.Mol Ther. 2008 Oct;16(10):1695-702.
  • Wu J, Williams JP, Rizvi TA, Kordich JJ, Witte D, Meijer D, Stemmer-Rachamimov AO, Cancelas JA, Ratner N.Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells.Cancer Cell. 2008 Feb;13(2):105-16.
  • Huang S, Vader D, Wang Z, Stemmer-Rachamimov A, Weitz DA, Dai G, Rosen BR, Deisboeck TS.Using magnetic resonance microscopy to study the growth dynamics of a glioma spheroid in collagen I: A case study.BMC Med Imaging. 2008;8:3.
  • Gabeau-Lacet D, Grant E, Stemmer-Rachamimov A, Yock T, Tarbell NJ.Sellar abnormalities in female first-degree relatives.Clin Neurol Neurosurg. 2008 Feb;110(2):202-6.
  • Samuels MA, Gonzalez RG, Kim AY, Stemmer-Rachamimov A.Case records of the Massachusetts General Hospital. Case 34-2007. A 77-year-old man with ear pain, difficulty speaking, and altered mental status.N Engl J Med. 2007 Nov 8;357(19):1957-65.
  • James MF, Lelke JM, Maccollin M, Plotkin SR, Stemmer-Rachamimov AO, Ramesh V, Gusella JF.Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.Neurobiol Dis. 2008 Feb;29(2):278-92.
  • Kalamarides M, Stemmer-Rachamimov AO, Takahashi M, Han ZY, Chareyre F, Niwa-Kawakita M, Black PM, Carroll RS, Giovannini M.Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.Brain Pathol. 2008 Jan;18(1):62-70.
  • Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y, Kaufman CS, Kaur B, Lawler SE, Lee RJ, Marsh CB, Brat DJ, van Rooijen N, Stemmer-Rachamimov AO, Hochberg FH, Weissleder R, Martuza RL, Chiocca EA.Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses.Cancer Res. 2007 Oct 1;67(19):9398-406.
  • Desantis SM, Houseman EA, Coull BA, Stemmer-Rachamimov A, Betensky RA.A penalized latent class model for ordinal data.Biostatistics. 2008 Apr;9(2):249-62.
  • Lessell S, Kim JW, Hatton MP, Stemmer-Rachamimov A, Thiagalingham S, Rubin PA.Clinical without histopathological manifestations of inflammation in a patient with primary intraorbital optic nerve sheath meningioma.J Neuroophthalmol. 2007 Jun;27(2):104-6.
  • Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO.Treatment of Implantable NF2 Schwannoma Tumor Models with Oncolytic Herpes Simplex Virus G47Delta.Cancer Gene Ther. 2007 May;14(5):460-7.
  • O'Neill GN, Gonzalez RG, Cros DP, Ackerman RH, Brown RH, Stemmer-Rachamimov A.Case records of the Massachusetts General Hospital. Case 22-2006--a 77-year-old man with a rapidly progressive gait disorder.N Engl J Med. 2006 Jul 20;355(3):296-304.
  • Brown AB, Mahmood U, Cortes ML, Tang Y, Dai G, Stemmer-Rachamimov A, Prabhakar S, Leishear K, Onda H, Kwiatkowski D, Weissleder R, Breakefield X.Magnetic resonance imaging and characterization of spontaneous lesions in a transgenic mouse model of tuberous sclerosis as a model for endothelial cell-based transgene delivery.Hum Gene Ther. 2005 Dec;16(12):1367-76.
  • Dong S, Nutt CL, Betensky RA, Stemmer-Rachamimov AO, Denko NC, Ligon KL, Rowitch DH, Louis DN.Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma.J Neuropathol Exp Neurol. 2005 Nov;64(11):948-955.
  • Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer-Rachamimov AO, Ramesh V, Gusella J, MacCollin M.Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma.Cancer Genet Cytogenet. 2005 Oct 15;162(2):135-9.
  • Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO.YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.Clin Cancer Res. 2005 Mar 15;11(6):2258-64.
  • Nestler U, Wakimoto H, Siller-Lopez F, Aguilar LK, Chakravarti A, Muzikansky A, Stemmer-Rachamimov A, Chiocca EA, Aguilar-Cordova E, Hochberg FH.The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects.J Neurooncol. 2004 Mar-Apr;67(1-2):177-88.
  • Niida Y, Stemmer-Rachamimov AO, Logrip M, Tapon D, Perez R, Kwiatkowski DJ, Sims K, MacCollin M, Louis DN, Ramesh V.Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions.Am J Hum Genet. 2001 Sep;69(3):493-503.
  • Stemmer-Rachamimov AO, Nielsen GP, Rosenberg AE, Louis DN, Jones D, Ramesh V, Gusella JF, Jacoby LB.The NF2 gene and merlin protein in human osteosarcomas.Neurogenetics. 1998 Dec;2(1):73-4.
  • Stemmer-Rachamimov AO, Ino Y, Lim ZY, Jacoby LB, MacCollin M, Gusella JF, Ramesh V, Louis DN.Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2.J Neuropathol Exp Neurol. 1998 Dec;57(12):1164-7.
  • Stemmer-Rachamimov AO, Xu L, Gonzalez-Agosti C, Burwick JA, Pinney D, Beauchamp R, Jacoby LB, Gusella JF, Ramesh V, Louis DN.Universal absence of merlin, but not other ERM family members, in schwannomas.Am J Pathol. 1997 Dec;151(6):1649-54.